These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 30954317)

  • 1. Aminosalicylates, thiopurines and methotrexate in inflammatory bowel disease: Is it possible to discontinue the treatment?
    Sedano Muñoz R; Quera Pino R; Ibáñez Lazo P; Figueroa Corona C; Flores Pérez L
    Gastroenterol Hepatol; 2019 May; 42(5):339-347. PubMed ID: 30954317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease.
    Gisbert JP; Chaparro M; Gomollón F
    World J Gastroenterol; 2011 Aug; 17(30):3467-78. PubMed ID: 21941413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoprophylaxis of colorectal cancer in inflammatory bowel disease: current concepts.
    Levine JS; Burakoff R
    Inflamm Bowel Dis; 2007 Oct; 13(10):1293-8. PubMed ID: 17567870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine.
    Hande S; Wilson-Rich N; Bousvaros A; Zholudev A; Maurer R; Banks P; Makrauer F; Reddy S; Burakoff R; Friedman S
    Inflamm Bowel Dis; 2006 Apr; 12(4):251-7. PubMed ID: 16633046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methotrexate in inflammatory bowel disease: A primer for gastroenterologists.
    AlAmeel T; Al Sulais E; Raine T
    Saudi J Gastroenterol; 2022; 28(4):250-260. PubMed ID: 35042318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conventional treatment of Crohn's disease: objectives and outcomes.
    Rutgeerts PJ
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S2-8. PubMed ID: 11380039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance of remission in Crohn's disease: current and emerging therapeutic options.
    Brookes MJ; Green JR
    Drugs; 2004; 64(10):1069-89. PubMed ID: 15139787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methotrexate for induction of remission in refractory Crohn's disease.
    McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
    Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease.
    Bermejo F; Aguas M; Chaparro M; Domènech E; Echarri A; García-Planella E; Guerra I; Gisbert JP; López-Sanromán A;
    Gastroenterol Hepatol; 2018 Mar; 41(3):205-221. PubMed ID: 29357999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low dose methotrexate in inflammatory bowel disease: current status and future directions.
    Schröder O; Stein J
    Am J Gastroenterol; 2003 Mar; 98(3):530-7. PubMed ID: 12650783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving treatment strategies for inflammatory bowel disease.
    Hanauer SB; Dassopoulos T
    Annu Rev Med; 2001; 52():299-318. PubMed ID: 11160781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacology of inflammatory bowel disease therapies.
    Sandborn WJ; Faubion WA
    Curr Gastroenterol Rep; 2000 Dec; 2(6):440-5. PubMed ID: 11079044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Questions and answers on the role of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease].
    Gisbert JP; Gomollón F; Maté J; Pajares JM
    Gastroenterol Hepatol; 2002; 25(6):401-15. PubMed ID: 12069704
    [No Abstract]   [Full Text] [Related]  

  • 15. Interaction of 6-mercaptopurine and azathioprine with 5-aminosalicylic acid agents.
    Present DH
    Gastroenterology; 2000 Jul; 119(1):276. PubMed ID: 10928833
    [No Abstract]   [Full Text] [Related]  

  • 16. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience with the use of low-dose methotrexate for inflammatory bowel disease.
    Soon SY; Ansari A; Yaneza M; Raoof S; Hirst J; Sanderson JD
    Eur J Gastroenterol Hepatol; 2004 Sep; 16(9):921-6. PubMed ID: 15316419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Classical medications in the treatment of inflammatory bowel diseases].
    Duvnjak M; Bilić A; Barsić N; Tomasić V; Stojsavljević S
    Acta Med Croatica; 2013 Apr; 67(2):111-24. PubMed ID: 24471294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Conservative therapy of inflammatory bowel diseases].
    Nagy F
    Orv Hetil; 2002 Dec; 143(50):2763-8. PubMed ID: 12583315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug resistance in inflammatory bowel diseases.
    Moreau J; Mas E
    Curr Opin Pharmacol; 2015 Dec; 25():56-61. PubMed ID: 26645664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.